Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21032736 | 0.84 | FOLH1 (0.51) | FOLH1SMN1; SMN2 | |
| SCHEMBL19975584 | 0.83 | FOLH1 (0.36) | FOLH1NOD1CPB2 | |
| SCHEMBL19970336 | 0.83 | FOLH1 (0.36) | FOLH1NOD1CPB2 | |
| SCHEMBL21032104 | 0.81 | GLP1R (0.41) | FOLH1NOD1 | |
| SCHEMBL19975587 | 0.80 | GNPAT (0.37) | FOLH1NOD1SMN1; SMN2CPB2 | |
| SCHEMBL21534104 | 0.79 | GLP1R (0.48) | FOLH1NOD1 | |
| SCHEMBL21031586 | 0.78 | FOLH1 (0.47) | FOLH1CPB2 | |
| SCHEMBL21032263 | 0.74 | FOLH1 (0.60) | FOLH1CPB2 | |
| SCHEMBL19975586 | 0.73 | CTSK (0.34) | NOD1 | |
| SCHEMBL5949922 | 0.70 | TDP1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463588-B2 | Cosmetic composition for anti-aging or alleviating skin redness, and medicinal composition for preventing and treating skin inflammatory diseases, containing compound inducing increase in expression of adiponectin | INCOSPHARM CORPORATION (KR) | 2019-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10463588-B2 | Cosmetic composition for anti-aging or alleviating skin redness, and medicinal composition for preventing and treating skin inflammatory diseases, containing compound inducing increase in expression of adiponectin | ADIPOR1, ADIPOR2, RBP1 | FOLH1 4072/4885NOD1 3618/4885SMN1; SMN2 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.